{"id":23875,"date":"2013-09-06T12:51:17","date_gmt":"2013-09-06T17:51:17","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=23875"},"modified":"2018-04-14T02:09:26","modified_gmt":"2018-04-14T07:09:26","slug":"23875","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/23875\/","title":{"rendered":"Not\u00edcias e notas de sa\u00fade animal de 6 de setembro de 2013"},"content":{"rendered":"

vers\u00e3o impressa<\/a><\/p>\n

***********************************
\nBrakke Consulting's
\nNot\u00edcias e notas de sa\u00fade animal de 6 de setembro de 2013
\n<\/strong>Copyright \u00a9 Brakke Consulting, Inc.
\n 
\nEditor: Lynn Fondon DVM MBA
\n************************************
\nNAS NOTICIAS
\n 
\nNovidades da Brakke Consulting
\n<\/u>AnimalHealthJobs.com
\nSemin\u00e1rio de Due Diligence<\/p>\n

not\u00edcias de ganhos
\n<\/u>G\u00eanero
\n 
\noutras not\u00edcias
\n<\/u>Bayer
\nBoehringer Ingelheim
\nVerde Global
\nMerial
\nNovartis (Zobuxa)
\nNovartis (Fl\u00f3rvio)
\nNovartis (Milbemax)
\nTerap\u00eautica Ogenx
\nPiemonte Sa\u00fade Animal
\nputney
\n 
\n************************************
\nBRAKKE CONSULTING, INC.
\nSemin\u00e1rio de Due Diligence.<\/strong><\/p>\n

A Brakke Consulting est\u00e1 planejando uma atualiza\u00e7\u00e3o e repeti\u00e7\u00e3o de seu conceituado semin\u00e1rio de dois dias sobre due diligence e outras quest\u00f5es relacionadas a aquisi\u00e7\u00f5es, desinvestimentos, transfer\u00eancia e licenciamento de propriedade intelectual (PI). O semin\u00e1rio ter\u00e1 um foco especial em aquisi\u00e7\u00f5es de pequeno e m\u00e9dio porte e na transfer\u00eancia e licenciamento de PI.
\n 
\nA taxa de inscri\u00e7\u00e3o ser\u00e1 de aproximadamente $1.500 para o semin\u00e1rio presencial de dois dias, que ser\u00e1 realizado no final do outono na \u00e1rea de Kansas City.<\/p>\n

Esperamos obter um senso de interesse no semin\u00e1rio. Sem compromisso, se voc\u00ea acha que pode comparecer, envie um e-mail para Joel Adamson (jadamson@brakkeconsulting.com<\/a>) ou John Mannhaupt (jmannhaupt@brakkeconsulting.com<\/a>) indicando que voc\u00ea pode participar, ou provavelmente participaria, de tal semin\u00e1rio. Agradecemos o seu feedback.
\n 
\nwww.BrakkeConsulting.com<\/a>
\n 
\n***********************************
\nRELEASES DE RESULTADOS DA EMPRESA
\n 
\n> Genus reportou resultados financeiros para o ano encerrado em 30 de junho de 2013. A empresa reportou um lucro operacional de GBP 37,2 milh\u00f5es ($58,1 milh\u00f5es) sobre receitas de GBP 345 milh\u00f5es ($539 milh\u00f5es) no ano encerrado em 30 de junho de 2013, em compara\u00e7\u00e3o com GBP 54,2 milh\u00f5es e GBP 342 milh\u00f5es nos 12 meses anteriores. (Farm\u00e1cia Animal) 
\n 
\n************************************
\nCOMUNICADOS DE NOT\u00cdCIAS DA EMPRESA
\n 
\n> A Global Green, Inc. anunciou a assinatura de um acordo com a Merial Ltd., para conduzir uma avalia\u00e7\u00e3o interna da tecnologia patenteada de vacinas Salmog\u00eanicas da Global Green. Salmogenics \u00e9 uma vacina de salmonela injetada no ovo antes que o pintinho seja chocado. Na conclus\u00e3o da avalia\u00e7\u00e3o, a Merial tem a primeira op\u00e7\u00e3o de firmar um contrato de licen\u00e7a com a Global Green para a fabrica\u00e7\u00e3o, distribui\u00e7\u00e3o e venda da vacina. (Observa\u00e7\u00e3o do mercado) 
\n 
\n> A FDA anunciou a aprova\u00e7\u00e3o de uma nova aprova\u00e7\u00e3o abreviada de medicamento animal para os comprimidos de Zobuxa (enrofloxacina) da Novartis para tratamento de doen\u00e7as caninas e felinas associadas a bact\u00e9rias suscet\u00edveis \u00e0 enrofloxacina. (FDA)  
\n 
\n> A FDA anunciou a aprova\u00e7\u00e3o abreviada de um novo medicamento animal para a solu\u00e7\u00e3o concentrada Florvio 2.3% da Novartis (florfenicol) para o tratamento da doen\u00e7a respirat\u00f3ria su\u00edna. (FDA) 
\n 
\n> A FDA anunciou a aprova\u00e7\u00e3o de uma nova aprova\u00e7\u00e3o abreviada de medicamento animal para a pomada de mupirocina 2% de Putney para o tratamento t\u00f3pico de infec\u00e7\u00f5es bacterianas caninas da pele. (FDA)
\n 
\n> A FDA anunciou a aprova\u00e7\u00e3o de uma nova aprova\u00e7\u00e3o abreviada de medicamento animal para os comprimidos mastig\u00e1veis Librevia (carprofeno) da Piedmont Animal Health para o al\u00edvio da dor e inflama\u00e7\u00e3o em c\u00e3es. (FDA) 
\n 
\n> A FDA informou que a Ogenx Therapeutics recebeu uma designa\u00e7\u00e3o de Minor Use Minor Species (MUMS) para o geroxane para duas indica\u00e7\u00f5es: para o tratamento de linfoma em c\u00e3es e para o tratamento de mastocitomas n\u00e3o ressec\u00e1veis de Grau II e III em c\u00e3es que n\u00e3o receberam terapia anterior, exceto corticoster\u00f3ides. (FDA)
\n 
\n> UE A Boehringer Ingelheim Animal Health anunciou o lan\u00e7amento europeu do Semintra (telmisartan1), o primeiro bloqueador dos receptores da angiotensina a receber uma autoriza\u00e7\u00e3o de comercializa\u00e7\u00e3o em medicina veterin\u00e1ria. Semintra est\u00e1 licenciado para a redu\u00e7\u00e3o da perda indesejada de prote\u00ednas atrav\u00e9s da urina (protein\u00faria) associada \u00e0 doen\u00e7a renal cr\u00f3nica em gatos. Semintra est\u00e1 dispon\u00edvel na forma de solu\u00e7\u00e3o oral de 4 mg\/ml. (Farm\u00e1cia Animal)
\n 
\n> UE A Novartis Animal Health anunciou que seu verm\u00edfugo canino Milbemax (milbemicina oxima, praziquantel) recebeu novas indica\u00e7\u00f5es na Uni\u00e3o Europ\u00e9ia para vermes pulmonares e oculares. (Farm\u00e1cia Animal)
\n 
\n> NOVA ZEL\u00c2NDIA A divis\u00e3o de sa\u00fade animal da Bayer HealthCare anunciou a abertura de um novo centro de pesquisa na Nova Zel\u00e2ndia. O Centro de Inova\u00e7\u00e3o e Desenvolvimento (CID) com sede em Auckland est\u00e1 localizado no site da Bayer em Glenfield, substituindo um laborat\u00f3rio menor em seu site de produ\u00e7\u00e3o de Manukau. (Farm\u00e1cia Animal) 
\n 
\n***********************************
\nNOT\u00cdCIAS DE SA\u00daDE ANIMAL
\n 
\n> M\u00c9XICO \u2013 GRIPE AVI\u00c1RIA O M\u00e9xico notificou dois novos surtos de gripe avi\u00e1ria altamente patog\u00eanica (HPAI) H7N3, o primeiro em um bando de codornas de aldeia e o segundo em um bando de poedeiras comerciais. As medidas de controlo anteriormente aplicadas continuam em curso, incluindo a vacina\u00e7\u00e3o de aves em risco e vigil\u00e2ncia epidemiol\u00f3gica a n\u00edvel nacional. (ThePoultrySite.com)
\n 
\n> EUA \u2013 EDUCA\u00c7\u00c3O VETERIN\u00c1RIA A Montana aprovou a cria\u00e7\u00e3o e o financiamento do Programa Cooperativo de Medicina Veterin\u00e1ria de Montana em coopera\u00e7\u00e3o com a Faculdade de Medicina Veterin\u00e1ria da Washington State University. Dez alunos de Montana far\u00e3o seu primeiro ano de aulas do programa veterin\u00e1rio no estado de Montana e, em seguida, ir\u00e3o para o WSU CVM para o restante de sua educa\u00e7\u00e3o. (alimentos)
\n 
\n> EUA \u2013 VACINA CONTRA A RAIVA Pacotes de vacina oral contra a raiva lan\u00e7ados pelo USDA em Nova York, Ohio, New Hampshire, Vermont e West Virginia mostraram-se eficazes em guaxinins, coiotes e raposas, mas n\u00e3o induzem prote\u00e7\u00e3o contra a raiva em gamb\u00e1s. Este \u00e9 o terceiro teste de vacina contra a vida selvagem do USDA. (AVMA SmartBrief \u2013 Portland Press Herald)
\n 
\n************************************
\nANIMALHEALTHJOBS.COM
\nO melhor lugar na web para encontrar candidatos qualificados!<\/strong><\/p>\n

www.AnimalHealthJobs.com \u00e9 o principal site de recrutamento para a ind\u00fastria de sa\u00fade animal.<\/p>\n

Um cliente que recentemente postou um emprego no AnimalHealthJobs.com afirma: \u201cTivemos uma resposta excepcional aos nossos an\u00fancios por meio do Animal Health Jobs, o que foi fant\u00e1stico; obrigado por um servi\u00e7o de alta qualidade.\u201d<\/p>\n

Quando precisar de profissionais qualificados, pense primeiro na Brakke Consultoria e Sa\u00fade Animal.<\/p>\n

www.AnimalHealthJobs.com
\n 
\n***********************************
\nPONTO DE VISTA DA BRAKKE CONSULTORIA<\/p>\n

Dever\u00edamos estar entrando na temporada de outono, mas em algumas partes dos EUA estamos enfrentando um clima muito quente e seco. N\u00e3o deveria ser 102 graus em 4 de setembro, mas foi em Dallas.<\/p>\n

Nas \u00faltimas duas semanas, tivemos a oportunidade de interagir com v\u00e1rios gerentes seniores em v\u00e1rios locais. Parece haver um consenso de que 2013 n\u00e3o ser\u00e1 um ano de crescimento de receita para a sa\u00fade animal. O clima no in\u00edcio do ano, juntamente com grandes estoques de produtos em algumas das principais categorias de produtos, limitaram as oportunidades de receita do segundo e terceiro trimestres.<\/p>\n

A boa not\u00edcia \u00e9 que a economia continua melhorando lentamente, o que deve aumentar as compras do consumidor de produtos pet e prote\u00ednas animais neste outono. O aumento do n\u00edvel de interesse da comunidade financeira em sa\u00fade animal \u00e9 um dos principais indicadores sobre o futuro da ind\u00fastria. Se as empresas continuarem a ter um bom desempenho, haver\u00e1 muito capital para alimentar um novo crescimento.<\/p>\n

Tenha um \u00f3timo fim de semana!!<\/p>\n

Ron Brakke
\n 
\n**********************************
\nEste boletim eletr\u00f4nico \u00e9 propriedade exclusiva da Brakke Consulting, Inc.
\nQualquer uso do conte\u00fado deste documento deve ser aprovado e devidamente atribu\u00eddo \u00e0 Brakke Consulting, Inc.
\nPara obter mais informa\u00e7\u00f5es sobre os servi\u00e7os e estudos sindicados da Brakke Consulting, visite nosso website em www.brakkeconsulting.com<\/a>.
\n 
\nBrakke Consulting, Inc.
\n12005 Ford Rd., Suite 530
\nDallas, TX 75234 EUA<\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

vers\u00e3o impressa *********************************** Not\u00edcias e notas sobre sa\u00fade animal da Brakke Consulting para 6 de setembro de 2013 Copyright \u00a9 Brakke Consulting, Inc. Editor: Lynn Fondon DVM MBA *************************************** NO NOT\u00cdCIAS Not\u00edcias da Brakke Consulting AnimalHealthJobs.com Not\u00edcias sobre ganhos do Semin\u00e1rio de Due Diligence G\u00eanero outras not\u00edcias Bayer Boehringer Ingelheim Global Green Merial Novartis (Zobuxa) Novartis (Florvio) Novartis (Milbemax) Ogenx Therapeutics Piedmont Animal Health Putney *********** ************************* BRAKKE CONSULTING, INC. Semin\u00e1rio de Due Diligence. A Brakke Consulting est\u00e1 planejando uma atualiza\u00e7\u00e3o e repeti\u00e7\u00e3o de seu conceituado semin\u00e1rio de dois dias sobre due diligence e outras quest\u00f5es relacionadas a aquisi\u00e7\u00f5es, desinvestimentos, transfer\u00eancia de propriedade intelectual (PI) e licenciamento. O semin\u00e1rio ter\u00e1 foco especial em aquisi\u00e7\u00f5es de pequeno e m\u00e9dio porte e em transfer\u00eancia e licenciamento de propriedade intelectual. A taxa de inscri\u00e7\u00e3o ser\u00e1 de aproximadamente $1.500 para o semin\u00e1rio presencial de dois dias, que ser\u00e1 realizado no final do outono na \u00e1rea de Kansas City. Esperamos despertar o interesse no semin\u00e1rio. Sem compromisso, se voc\u00ea acha que pode participar, envie um e-mail para Joel Adamson (jadamson@brakkeconsulting.com) ou John Mannhaupt (jmannhaupt@brakkeconsulting.com) indicando que voc\u00ea pode participar, ou provavelmente participaria, de tal semin\u00e1rio . Agradecemos seu feedback. www.BrakkeConsulting.com *********************************** DIVULGA\u00c7\u00d5ES DE RESULTADOS DA EMPRESA > Genus relatou resultados financeiros para o ano encerrado em 30 de junho de 2013. A empresa relatou um lucro operacional de GBP<\/p>\n

Ver postagem completa<\/a><\/div>\n

;<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-23875","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"\nNews from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/23875\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"print version *********************************** Brakke Consulting’s Animal Health News & Notes for September 6, 2013 Copyright © Brakke Consulting, Inc.   Editor: Lynn Fondon DVM MBA ************************************ IN THE NEWS   Brakke Consulting news AnimalHealthJobs.com Due Diligence Seminar earnings news Genus   other news Bayer Boehringer Ingelheim Global Green Merial Novartis (Zobuxa) Novartis (Florvio) Novartis (Milbemax) Ogenx Therapeutics Piedmont Animal Health Putney   ************************************ BRAKKE CONSULTING, INC. Due Diligence Seminar. Brakke Consulting is planning an update and repeat of its highly regarded two-day seminar on due diligence and other issues related to acquisitions, divestitures, intellectual property (IP) transfer and licensing. The seminar will have a special focus on small to mid-size acquisitions and on IP transfer and licensing.   The registration fee will be approximately $1,500 for the two-day, in-person seminar, which will be held in the late fall in the Kansas City area. We are hoping to get a sense of interest in the seminar. With no obligation, if you think you may attend please send an e-mail to Joel Adamson (jadamson@brakkeconsulting.com)  or John Mannhaupt (jmannhaupt@brakkeconsulting.com)  indicating that you may attend, or would likely attend, such a seminar. We appreciate your feedback.   www.BrakkeConsulting.com   *********************************** COMPANY EARNINGS RELEASES   > Genus reported financial results for the year ended June 30, 2013. The company reported an operating profit of GBPView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/23875\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2013-09-06T17:51:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-04-14T07:09:26+00:00\" \/>\n<meta name=\"author\" content=\"Brakke Consulting\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brakke Consulting\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/23875\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23875\/\"},\"author\":{\"name\":\"Brakke Consulting\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"headline\":\"Animal Health News & Notes for September 6, 2013\",\"datePublished\":\"2013-09-06T17:51:17+00:00\",\"dateModified\":\"2018-04-14T07:09:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23875\/\"},\"wordCount\":1183,\"articleSection\":[\"Newsletter\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/23875\/\",\"url\":\"https:\/\/brakkeconsulting.com\/23875\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2013-09-06T17:51:17+00:00\",\"dateModified\":\"2018-04-14T07:09:26+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/23875\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/23875\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/23875\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Animal Health News & Notes for September 6, 2013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6\",\"name\":\"Brakke Consulting\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/23875\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"print version *********************************** Brakke Consulting’s Animal Health News & Notes for September 6, 2013 Copyright © Brakke Consulting, Inc.   Editor: Lynn Fondon DVM MBA ************************************ IN THE NEWS   Brakke Consulting news AnimalHealthJobs.com Due Diligence Seminar earnings news Genus   other news Bayer Boehringer Ingelheim Global Green Merial Novartis (Zobuxa) Novartis (Florvio) Novartis (Milbemax) Ogenx Therapeutics Piedmont Animal Health Putney   ************************************ BRAKKE CONSULTING, INC. Due Diligence Seminar. Brakke Consulting is planning an update and repeat of its highly regarded two-day seminar on due diligence and other issues related to acquisitions, divestitures, intellectual property (IP) transfer and licensing. The seminar will have a special focus on small to mid-size acquisitions and on IP transfer and licensing.   The registration fee will be approximately $1,500 for the two-day, in-person seminar, which will be held in the late fall in the Kansas City area. We are hoping to get a sense of interest in the seminar. With no obligation, if you think you may attend please send an e-mail to Joel Adamson (jadamson@brakkeconsulting.com)  or John Mannhaupt (jmannhaupt@brakkeconsulting.com)  indicating that you may attend, or would likely attend, such a seminar. We appreciate your feedback.   www.BrakkeConsulting.com   *********************************** COMPANY EARNINGS RELEASES   > Genus reported financial results for the year ended June 30, 2013. The company reported an operating profit of GBPView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/23875\/","og_site_name":"Brakke Consulting Website","article_published_time":"2013-09-06T17:51:17+00:00","article_modified_time":"2018-04-14T07:09:26+00:00","author":"Brakke Consulting","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Brakke Consulting","Tempo estimado de leitura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/23875\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/23875\/"},"author":{"name":"Brakke Consulting","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"headline":"Animal Health News & Notes for September 6, 2013","datePublished":"2013-09-06T17:51:17+00:00","dateModified":"2018-04-14T07:09:26+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/23875\/"},"wordCount":1183,"articleSection":["Newsletter"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/23875\/","url":"https:\/\/brakkeconsulting.com\/23875\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2013-09-06T17:51:17+00:00","dateModified":"2018-04-14T07:09:26+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/23875\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/23875\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/23875\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Animal Health News & Notes for September 6, 2013"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/a5d2c4b59040e54bfe8f4f41f77e04d6","name":"Brakke Consultoria","url":"https:\/\/brakkeconsulting.com\/pt\/author\/i5ww2018\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=23875"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23875\/revisions"}],"predecessor-version":[{"id":25423,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/23875\/revisions\/25423"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=23875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=23875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=23875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}